Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Slaughter, Jonathan L ^a,b   Stenger, Michael R ^a,b   Reagan, Patricia B ^b,c   Jadcherla, Sudarshan R ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; OXYGEN; GLUCOCORTICOID;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHILD HOSPITALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NEBULIZATION; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; BRONCHOPULMONARY DYSPLASIA; HOSPITAL PATIENT; INHALATIONAL DRUG ADMINISTRATION; LOW BIRTH WEIGHT; NEWBORN;

ADMINISTRATION, INHALATION; BECLOMETHASONE; BRONCHOPULMONARY DYSPLASIA; BUDESONIDE; FLUTICASONE; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INPATIENTS; RETROSPECTIVE STUDIES;

EID: 84907000350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106838     Document Type: Article

References (37)

1. Watterberg K (2012) Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 39: 47-59.
2. Halliday HL, Ehrenkranz RA, Doyle LW (2010) Early (, 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev: CD001146.
3. Cole CH (2001) Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: routes of administration compared. Semin Neonatol 6: 343- 350.
4. Lister P, Iles R, Shaw B, Ducharme F (2000) Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev: CD002311.
5. Onland W, Offringa M, van Kaam A (2012) Late (>/= 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 4: CD002311.
6. Shah SS, Ohlsson A, Halliday HL, Shah VS (2012) Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 5: CD002058.
7. Shah SS, Ohlsson A, Halliday HL, Shah VS (2012) Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 5: CD002057.
8. Shah VS, Ohlsson A, Halliday HL, Dunn M (2012) Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 5: CD001969.
9. Maas C, Poets CF, Bassler D (2010) Survey of practices regarding utilization of inhaled steroids in 223 German neonatal units. Neonatology 98: 404-408.
10. Porter KB, Garner SS (2005) Survey of the use of corticosteroids among neonatal intensive care units for the prevention or treatment of bronchopulmonary dysplasia. J Pediatr Pharmacol Ther 10: 90-99.
11. Slaughter JL, Stenger MR, Reagan PB (2013) Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics 131: 716-723.
12. Walsh MC, Szefler S, Davis J, Allen M, Van Marter L, et al. (2006) Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117: S52- 56.
13. Bancalari EH, Jobe AH (2012) The respiratory course of extremely preterm infants: A dilemma for diagnosis and terminology. J Pediatr 161: 585-588.
14. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, et al. (2005) Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116: 1353-1360.
15. Arnon S, Grigg J, Silverman M (1996) Effectiveness of budesonide aerosol in ventilator-dependent preterm babies: A preliminary report. Pediatr Pulmonol 21: 231-235.
16. LaForce WR, Brudno DS (1993) Controlled trial of beclomethasone dipropionate by nebulization in oxygen- And ventilator-dependent infants. J Pediatr 122: 285-288.
17. Pappagallo M, Abbasi S, Bhutani VK (1998) Respiratory and systemic effects of inhaled dexamethasone on ventilator dependant preterm infants at risk for bronchopulmonary dysplasia. Indian J Pediatr 65: 273-282.
18. Dugas MA, Nguyen D, Frenette L, Lachance C, St-Onge O, et al. (2005) Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 115: e566-572.
19. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, et al. (1999) Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340: 1005-1010.
20. Farney KD, Kuehne BT, Gibson LA, Nelin LD, Shepherd EG (2013) In Vitro Evaluation of Radiolabeled Aerosol Delivery via a Variable Flow Infant CPAP System. Respir Care.
21. Mazela J, Polin RA (2011) Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur J Pediatr 170: 433-444.
22. Kohler E, Jilg G, Avenarius S, Jorch G (2008) Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed 93: F275-279.
23. Watterberg KL, Clark AR, Kelly HW, Murphy S (1991) Delivery of aerosolized medication to intubated babies. Pediatr Pulmonol 10: 136-141.
24. Bassler D, Halliday HL, Plavka R, Hallman M, Shinwell ES, et al. (2010) The Neonatal European Study of Inhaled Steroids (NEUROSIS): An eu-funded international randomised controlled trial in preterm infants. Neonatology 97: 52-55.
25. Stockmann C, Fassl B, Gaedigk R, Nkoy F, Uchida DA, et al. (2013) Fluticasone Propionate Pharmacogenetics: CYP3A4∗22 Polymorphism and Pediatric Asthma Control. J Pediatr 162: 1222-1227. e2.
26. Moore CD, Roberts JK, Orton CR, Murai T, Fidler TP, et al. (2013) Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos 41: 379-389.
27. Roberts JK, Moore CD, Ward RM, Yost GS, Reilly CA (2013) Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharm Exp Ther 345: 308-316.
28. Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157: S1-53.
29. Ng PC, Fok TF, Wong GW, Lam CW, Lee CH, et al. (1998) Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 83: 2390-2393.
30. Cole CH, Shah B, Abbasi S, Demissie S, MacKinnon B, et al. (1999) Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr 135: 65-70.
31. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, et al. (2012) Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367: 904-912.
32. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, et al. (2008) Effect of long-term corticosteroid use on bone mineral density in children: A prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 122: e53-61.
33. McKeever T, Harrison TW, Hubbard R, Shaw D (2013) Inhaled Corticosteroids and the Risk of Pneumonia in people with Asthma: A case control study. Chest.
34. Buzzi E, Manzoni P, Castagnola E, Benjamin DK Jr, Beghini R, et al. (2013) Candida pneumonia in a term infant after prolonged use of inhaled corticosteroids for bronchopulmonary dysplasia (BPD). Early Hum Dev 89 Suppl 1: S62-63.
35. Linder N, Kuint J, German B, Lubin D, Loewenthal R (1995) Hypertrophy of the tongue associated with inhaled corticosteroid therapy in premature infants. J Pediatr 127: 651-653.
36. Vandenbroucke JP (2006) What is the best evidence for determining harms of medical treatment? CMAJ 174: 645-646.
37. Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, et al. (2010) AHRQ series paper 4: Assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 63: 502-512.